Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer Metastatic: early-phase trial registry
11 of 18 indexed Breast Cancer Metastatic trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #953 of 28,707 conditions by registered trial count.
18 US clinical trials · 11 currently recruiting · #953 of 28,707 conditions by registered trial count
Breast Cancer Metastatic: 18 US clinical trials tracked, 11 recruiting.
Breast Cancer Metastatic is the subject of 18 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is Oncolytics Biotech, running 1 of these trials.
Enrollment posture brief
Registry condition breast-cancer-metastatic
OPEN 11 | RECR 61% | LATE 1 | EARLY 14 | RANK #953 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Child Behavior (61% recruiting · 18 trials)
Breast Cancer Metastatic lists 11 open slots (61% of 18 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer Metastatic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer Metastatic is recruiting above its size-band peers.
11 of 18 indexed trials (61.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer Metastatic trials is spread across many organizations.
Oncolytics Biotech accounts for 1 of 18 trials (5.6%). 18 distinct sponsors appear on at least one study for this condition label.
-
Most Breast Cancer Metastatic trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 18 trials that report a genuine target (sentinel values excluded). 13 of those (72.2%) plan for fewer than 100 participants.
-
Breast Cancer Metastatic research is mostly interventional.
16 interventional and 2 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
18 total, page 1 of 1
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
BriaCell Therapeutics Corporation
NCT06072612
Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
NCT07389967
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Incyclix Bio
NCT05735080
ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies
ALX Oncology
NCT07007559
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
NCT06439693
SLV-154 Treatment of Metastatic Solid Tumors
Solve Therapeutics
NCT06771219
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
Yale University
NCT06750484
Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy
The University of Texas Health Science Center at San Antonio
NCT07137871
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT06678269
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
General Oncology
NCT04150042
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
Calibr, a division of Scripps Research
NCT06878248
Screening For BCRL In Targeted Therapy For Breast Cancer
Massachusetts General Hospital
NCT05142800
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Who Achieved Durable Response by Anti-HER2 Treatment (HER2 CR)
Nagoya City University
NCT06663787
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Oncolytics Biotech
NCT04215146
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
The Methodist Hospital Research Institute
NCT03742245
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
Adrienne G. Waks
NCT06100874
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Merus B.V.
NCT03321981
DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer
Dizal Pharmaceuticals
NCT04509596
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Breast Cancer Metastatic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Breast Cancer Metastatic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Breast Cancer Metastatic page
18 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Breast Cancer Metastatic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Oncolytics Biotech sponsors the most Breast Cancer Metastatic trials on record, review their full trial history before evaluating a specific study. See Oncolytics Biotech's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Cancer Metastatic condition card totals 18 registered trials; most-linked intervention Paclitaxel; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.